signatera | Signatera – Circulating Tumor DNA Blood Test

Keyword	CPC	PCC	Volume	Score	Length of keyword
signatera	0.73	0.8	4584	41	9

Keyword	CPC	PCC	Volume	Score
signatera	0.35	0.6	5866	1
signatera testing	0.61	0.2	7156	8
signatera portal	0.02	1	2848	9
signatera blood test	1.96	0.9	9612	90
signatera login	0.84	0.4	6430	4
signatera oncology portal	1.29	0.9	7477	38
signatera ctdna	0.88	0.5	5074	94
signatera test results	0.82	0.5	2813	73
signatera mrd	1.48	0.7	3937	1
signatera natera	0.21	0.3	2353	42
signatera breast cancer	0.17	0.1	8185	42
signatera colon cancer	1	0.2	5397	40
signatera assay	1.13	0.9	7524	76
signatera cpt code	1.87	0.7	9155	68
signatera login portal	0.91	0.4	7967	98
signatera blood test for cancer	0.81	1	2505	94
signatera test cost	0.91	0.9	8598	63
signatera order form	0.75	0.6	7594	11
signatera ctdna test	1.41	0.7	5114	74

Search Results related to signatera on Search Engine

Signatera – Circulating Tumor DNA Blood Test | Natera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/

WEBSignatera™ is the first tumor-specific assay for truly individualized cancer care. Personalized design for every patient. Custom-built assay—based on the unique mutation signature of each patient’s tumor—identifies and tracks tumor mutations at the source.

DA: 67 PA: 39 MOZ Rank: 14

Signatera for Patients | Natera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/patients/

WEBSignatera™ is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools. Overview. Patient Information. Clinician Information. FAQ. Is MRD testing right for you?

DA: 42 PA: 90 MOZ Rank: 30

ctDNA Testing for Colon Cancer – Signatera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/clinicians/

WEBSignatera™ is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools.

DA: 50 PA: 32 MOZ Rank: 54

Testing for cancer recurrence creates a new limbo for patients
statnews.com

https://www.statnews.com/2023/10/29/ctdna-liquid-biopsy-signatera-cancer-recurrence-minimal-residual-disease/

WEBOct 29, 2023 · Signatera is a novel personalized assay designed around the patient’s tumor profile that can identify circulating tumor DNA (ctDNA) in the blood. It’s also known as a liquid biopsy. A positive...

DA: 65 PA: 28 MOZ Rank: 37

Detect relapse or progression early - Mayo
mayo.edu

https://ce.mayo.edu/sites/default/files/Signatera%20Patient%20Education.pdf

WEBSignatera is a new cancer-surveillance test that is personalized for each patient. Signatera is a custom-designed test that is generated based on each patient’s unique set of tumor mutations. Knowing earlier if your cancer is likely to recur or has progressed after treatment can help you have a more informed discussion with your

DA: 40 PA: 13 MOZ Rank: 34

Signatera FAQ | Natera
natera.com

https://www.natera.com/oncology/signatera-advanced-cancer-detection/faq/

WEBSignatera™ is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment, treatment response monitoring, and early recurrence monitoring. How is Signatera™ different from current biomarker tests? What can MRD testing tell me about my cancer?

DA: 60 PA: 10 MOZ Rank: 46

Cutting-edge test detects early tumor recurrence in some cancers
go.com

https://abcnews.go.com/GMA/Wellness/cutting-edge-test-detects-early-tumor-recurrence-cancers/story?id=78187359

WEBJun 10, 2021 · Signatera, a "tumor-informed" blood test developed by Natera, can detect circulating tumor DNA in the bloodstream for certain types of cancers.

DA: 88 PA: 73 MOZ Rank: 17

Natera Submits First PMA Module to the FDA for Signatera™
natera.com

https://investor.natera.com/news/news-details/2023/Natera-Submits-First-PMA-Module-to-the-FDA-for-Signatera/default.aspx

WEBOct 2, 2023 · About Signatera. Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.

DA: 62 PA: 33 MOZ Rank: 60

Signatera Tumor DNA Test via Dr. Kristi Funk & Pink Lotus
pinklotus.com

https://pinklotus.com/breastcenter/tumortest/

WEBSignatera is a cancer surveillance test uniquely personalized for each patient. This custom-designed test uses your cancer cells (obtained from the pathology slides) to determine a unique set of tumor mutations that belong to your cancer. A blood sample from you is then taken and analyzed for the presence of any of these mutations.

DA: 1 PA: 49 MOZ Rank: 76

Study: Signatera can help predict recurrence after colorectal …
colorectalcancer.org

https://colorectalcancer.org/article/study-signatera-can-help-predict-recurrence-after-colorectal-cancer-surgery

WEBJan 24, 2023. A study announced by Natera, the makers of a molecular residual disease (MRD) test called Signatera, showed the test’s ability to identify patients with stage II-IV colorectal cancer who are at an increased risk for recurrence after surgery.

DA: 65 PA: 26 MOZ Rank: 51